Author

K. Barthelemy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:phylogenetics / evolution· 1

Frequent Co-Authors

A. Nougairede· 3 shared C. Solas· 3 shared F. Touret· 3 shared G. Moureau· 3 shared J.-S. Driouich· 3 shared M. Cochin· 3 shared X. de Lamballerie· 3 shared M. Gilles· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Nougairede

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

J.-S. Driouich, M. Cochin, F. Touret, P.-R. Petit, M. Gilles, G. Moureau, K. Barthelemy, C. Laprie, T. Wattanakul, P. Chotsiri, R. M. Hoglund, J. Tarning, F. Escudie, I. Scandale, E. Chatelain, , A. Nougairede

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

bioRxiv · Dec 17, 2021Pathology

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

F. Touret, J.-S. Driouich, M. Cochin, P. R. Petit, M. Gilles, K. Barthelemy, G. Moureau, F.-X. MAHON, D. Malvy, C. Solas, X. de Lamballerie, A. Nougairede

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

bioRxiv · Nov 17, 2020Microbiology

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

J.-S. Driouich, M. Cochin, G. Lingas, G. Moureau, F. Touret, P.-R. Petit, G. Piorkowski, K. Barthelemy, B. Coutard, J. Guedj, X. de Lamballerie, C. Solas, A. Nougairede

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

bioRxiv · Jul 7, 2020Microbiology